001     141404
005     20240229112524.0
024 7 _ |2 doi
|a 10.1038/s41375-018-0239-1
024 7 _ |2 pmid
|a pmid:30131584
024 7 _ |2 ISSN
|a 0887-6924
024 7 _ |2 ISSN
|a 1476-5551
024 7 _ |a altmetric:47525836
|2 altmetric
037 _ _ |a DKFZ-2018-01910
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Prutsch, Nicole
|b 0
245 _ _ |a Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
260 _ _ |a London
|b Springer Nature
|c 2019
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1556279781_16123
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a TYK2 is a member of the JAK family of tyrosine kinases that is involved in chromosomal translocation-induced fusion proteins found in anaplastic large cell lymphomas (ALCL) that lack rearrangements activating the anaplastic lymphoma kinase (ALK). Here we demonstrate that TYK2 is highly expressed in all cases of human ALCL, and that in a mouse model of NPM-ALK-induced lymphoma, genetic disruption of Tyk2 delays the onset of tumors and prolongs survival of the mice. Lymphomas in this model lacking Tyk2 have reduced STAT1 and STAT3 phosphorylation and reduced expression of Mcl1, a pro-survival member of the BCL2 family. These findings in mice are mirrored in human ALCL cell lines, in which TYK2 is activated by autocrine production of IL-10 and IL-22 and by interaction with specific receptors expressed by the cells. Activated TYK2 leads to STAT1 and STAT3 phosphorylation, activated expression of MCL1 and aberrant ALCL cell survival. Moreover, TYK2 inhibitors are able to induce apoptosis in ALCL cells, regardless of the presence or absence of an ALK-fusion. Thus, TYK2 is a dependency that is required for ALCL cell survival through activation of MCL1 expression. TYK2 represents an attractive drug target due to its essential enzymatic domain, and TYK2-specific inhibitors show promise as novel targeted inhibitors for ALCL.
536 _ _ |0 G:(DE-HGF)POF3-313
|a 313 - Cancer risk factors and prevention (POF3-313)
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Gurnhofer, Elisabeth
|b 1
700 1 _ |a Suske, Tobias
|b 2
700 1 _ |a Liang, Huan Chang
|b 3
700 1 _ |a Schlederer, Michaela
|b 4
700 1 _ |a Roos, Simone
|b 5
700 1 _ |a Wu, Lawren C
|b 6
700 1 _ |a Simonitsch-Klupp, Ingrid
|b 7
700 1 _ |a Alvarez-Hernandez, Andrea
|b 8
700 1 _ |a Kornauth, Christoph
|b 9
700 1 _ |a Leone, Dario A
|b 10
700 1 _ |a Svinka, Jasmin
|b 11
700 1 _ |a Eferl, Robert
|b 12
700 1 _ |a Limberger, Tanja
|b 13
700 1 _ |a Aufinger, Astrid
|b 14
700 1 _ |a Shirsath, Nitesh
|b 15
700 1 _ |a Wolf, Peter
|b 16
700 1 _ |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|a Hielscher, Thomas
|b 17
|u dkfz
700 1 _ |0 0000-0003-2009-6305
|a Aberger, Fritz
|b 18
700 1 _ |a Schmoellerl, Johannes
|b 19
700 1 _ |a Stoiber, Dagmar
|b 20
700 1 _ |a Strobl, Birgit
|b 21
700 1 _ |a Jäger, Ulrich
|b 22
700 1 _ |a Staber, Philipp B
|b 23
700 1 _ |0 0000-0003-4289-2281
|a Grebien, Florian
|b 24
700 1 _ |0 0000-0003-0918-9463
|a Moriggl, Richard
|b 25
700 1 _ |a Müller, Mathias
|b 26
700 1 _ |a Inghirami, Giorgio G
|b 27
700 1 _ |0 0000-0003-1621-4954
|a Sanda, Takaomi
|b 28
700 1 _ |a Look, A Thomas
|b 29
700 1 _ |a Turner, Suzanne D
|b 30
700 1 _ |a Kenner, Lukas
|b 31
700 1 _ |a Merkel, Olaf
|b 32
773 _ _ |0 PERI:(DE-600)2008023-2
|a 10.1038/s41375-018-0239-1
|n 3
|p 696-709
|t Leukemia
|v 33
|x 1476-5551
|y 2019
909 C O |o oai:inrepo02.dkfz.de:141404
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|a Deutsches Krebsforschungszentrum
|b 17
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF3-313
|1 G:(DE-HGF)POF3-310
|2 G:(DE-HGF)POF3-300
|a DE-HGF
|l Krebsforschung
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b LEUKEMIA : 2017
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
915 _ _ |0 StatID:(DE-HGF)0110
|2 StatID
|a WoS
|b Science Citation Index
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
915 _ _ |0 StatID:(DE-HGF)9910
|2 StatID
|a IF >= 10
|b LEUKEMIA : 2017
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21